Interleukin 1 beta

Source: Wikipedia, the free encyclopedia.
(Redirected from
IL1B
)
IL1B
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_000576

NM_008361

RefSeq (protein)

NP_000567

NP_032387

Location (UCSC)Chr 2: 112.83 – 112.84 MbChr 2: 129.21 – 129.21 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Interleukin-1 beta (IL-1β) also known as leukocytic pyrogen, leukocytic endogenous mediator, mononuclear cell factor, lymphocyte activating factor and other names, is a

IL-1 alpha and IL-1 beta (this gene). IL-1β precursor is cleaved by cytosolic caspase 1
(interleukin 1 beta convertase) to form mature IL-1β.

Function

The fever-producing property of human leukocytic

interleukin-1 alpha and interleukin-1 beta.[6]

IL-1β is a member of the

cyclooxygenase-2 (PTGS2/COX2) by this cytokine in the central nervous system (CNS) is found to contribute to inflammatory pain hypersensitivity. This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2.[14]

IL-1β, in combination with

γδ T cells. This induction of expression is in the absence of additional signals. That suggests IL-1β is involved in modulation of autoimmune inflammation [15]

Different

Properties

Before cleavage by caspase 1, pro-IL-1β has a molecular weight of 37 kDa.[13] The molecular weight of the proteolytically processed IL-1β is 17.5 kDa. IL-1β has the following amino acid sequence:

  • APVRSLNCTL RDSQQKSLVM SGPYELKALH LQGQDMEQQV VFSMSFVQGE ESNDKIPVAL GLKEKNLYLS CVLKDDKPTL QLESVDPKNY PKKKMEKRFV FNKIEINNKL EFESAQFPNW YISTSQAENM PVFLGGTKGG QDITDFTMQF VSS

The physiological activity determined from the dose dependent proliferation of murine D10S cells is 2.5 x 108 to 7.1 x 108 units/mg.

IL-1β is present in other species of animals, however non-mammalian sequences of IL-1β lack a conserved cascase-1 cleavage site.[17][18][19]

Clinical significance

Increased production of IL-1β causes a number of different

autoinflammatory syndromes, most notably the monogenic conditions referred to as Cryopyrin-Associated Periodic Syndromes (CAPS), due to mutations in the inflammasome receptor NLRP3 which triggers processing of IL-1β.[20]

Intestinal dysbiosis has been observed to induce osteomyelitis through a IL-1β dependent manner.[21]

The presence of IL-1β has been also found in patients with multiple sclerosis (a chronic autoimmune disease of the central nervous system). However, it is not known exactly which cells produce IL-1β. Treatment of multiple sclerosis with glatiramer acetate or natalizumab has also been shown to reduce the presence of IL-1β or its receptor.[22]

Role in carcinogenesis

Several types of inflammasomes are suggested to play role in tumorgenesis due to their immunomodulatory properties, modulation of gut microbiota, differentiation and apoptosis. Over-expression of IL-1β caused by inflammasome may result in carcinogenesis. Some data suggest that

NLRP3 inflammasome polymorphisms is connected to malignancies such as colon cancer and melanoma. It was reported that IL-1β secretion was elevated in the lung adenocarcinoma cell line A549. It has also been shown in another study that IL-1β, together with IL-8, plays an important role in chemoresistance of malignant pleural mesothelioma by inducing expression of transmembrane transporters.[23] Another study showed that inhibition of inflammasome and IL-1β expression decreased development of cancer cells in melanoma.[24]

Furthermore, it has been found that in breast cancer cells, IL-1β activates p38 and p42/22 MAPK pathways which ultimately lead to the secretion of the RANK/RANKL inhibitor osteoprotegerin. Higher osteoprotegerin and IL-1β levels are a characteristic of breast cancer cells with a higher metastatic potential.[25]

In HIV-1 infections

The human immunodeficiency virus (HIV) infects cells of the immune system, such as macrophages, dendritic cells, and CD4+ T helper cells (TH). The latter can be infected by the virus in various ways with different fates depending on the state of activation of the T helper cell.[13]

Firstly, TH cells can die of viral lysis due to an active infection that produces enough virions to kill the cell. Secondly, CD4+ T cells can be infected by the virus but instead of producing more viral particles, the cell enters a latent phase. In this period, the T helper cells looks identical from the outside but any stressor could lead to the renewed production of HIV and its propagation to new immune cells. Lastly, the TH cell can become abortively infected, where the virus gets detected inside the cell and a programmed cell-death, known as pyroptosis, kills the infected cell. Pyroptosis is mediated via caspase-1 and is characterized by cell lysis and the secretion of IL-1β causing inflammation and attraction of more immune cells. This can create a cycle of CD4+ T cells getting abortively infect with HIV, dying of pyroptosis, new T helper cells arriving to the site of inflammation where they get infected again. The results is the depletion of T helper cells. Even though, levels of IL-1β in blood are not majorly different between HIV positive and negative individuals, studies have shown elevated levels of IL-1β of lymphatic tissue in HIV-infected individuals.[13]

In fact, the gut-associated lymphoid tissue (GALT) has a high density of immune cells as the gut is an interface between symbiotic gut microbes that should remain with the host and pathogenic bacteria that should not gain access into the circulatory system. If HIV-infection leads to the secretion of IL-1βin monocytes and macrophages, it causes inflammation of this area. The mucosal epithelial layer responds to this by producing less or altering the tight junction proteins which makes it easier for pathogenic microbes to move into the lamina propria. Here, the pathogens can further activate local immune cells and amplify the inflammatory response.[13]

Retinal degeneration

It has been shown that IL-1 family plays important role in inflammation in many degenerative diseases, such as age-related macular degeneration, diabetic retinopathy and retinitis pigmentosa. Significantly increased protein level of IL-1β has been found in the vitreous of diabetic retinopathy patient. The role of IL-1β has been investigated for potential therapeutic target for treatment of diabetic retinopathy. However, systemic using of canakinumab did not have an significant effect. The role of IL-1β in age-related macular degeneration has not been proven in patient, but in many animal models and in vitro studies it has been demonstrated the role of IL-1β in retinal pigmented epithelial cells and photoreceptor cells damage. NLRP3 inflammasome activate caspase-1 which catalyze cleavage of inactive cytosolic precursor pro-IL-1β to its mature form IL-1β. Retinal pigmented epithelial cells forms blood retinal barrier in human retina which is important for retinal metabolic activity, integrity and inhibition of immune cells infiltration. It has been shown that human retinal pigmented epithelial cells can secrete IL-1 β in exposure to oxidative stress. The inflammatory reaction leads to damage of retinal cells and infiltration of cells of the immune system. The inflammatory process including NLRP3 upregulation is one of the causes of age-related macular degeneration and other retinal diseases that lead to vision loss.[26][27][28] Additionally, it has been shown that caspase-1 is upregulated in the retina of diabetic patients, causing a higher production of IL-1β and subsequent death of retinal neurons.[29]

Neuroinflammation

Studies in mice on experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS) research, have found that blocking IL-1β could make the animals resistant to EAE. IL-1β led to the production of an antigen-specific pro-inflammatory subset of T helper cells (TH17). In combination with other cytokines, interleukin-1β can upregulate the production of the cytokine GM-CSF which is correlated to neuroinflammation. Detailed mechanisms on this front are yet to be elucidated.[30]

IL-1β has also been observed in elevated levels of the cerebrospinal fluid and brain tissues of Alzheimer patients. The amyloid-β plaques, that are characteristic of Alzheimer disease, are damage-associated molecular patterns (DAMPs) that are recognized by pattern recognition receptors (PRRs) and lead to the activation of microglia. Consequently, microglia release interleukin-1β among other cytokines. Nevertheless, the significance of IL-1β in Alzheimer disease and the onset of neuroinflammation still remains largely unknown.[30]

Lastly, in vitro studies have shown that IL-1β causes an increase in mitochondrial glutaminase activity. In response, there is excessive glutamate secretion which has a neurotoxic effect.[30]

As a therapeutic target

Anakinra is a recombinant and slightly modified version of the human interleukin 1 receptor antagonist protein. Anakinra blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the interleukin type 1 receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. Anakinra is marketed as Kineret and is approved in the US for treatment of RA, NOMID, DIRA.

Canakinumab is a human monoclonal antibody targeted at IL-1B, and approved in many countries for treatment of cryopyrin-associated periodic syndromes.

Regeneron targeting IL-1B, and approved in the US as Arcalyst.[31]

Orthographic note

Because many authors of scientific manuscripts make the minor error of using a homoglyph, sharp s (ß), instead of beta (β), mentions of "IL-1ß" [sic] often become "IL-1ss" [sic] upon automated transcoding (because ß transcodes to ss). This is why so many mentions of the latter appear in web search results.

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000125538 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000027398 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. PMID 6083565
    .
  6. ^ .
  7. .
  8. .
  9. .
  10. .
  11. .
  12. .
  13. ^ .
  14. ^ "Entrez Gene: IL1B interleukin 1, beta".
  15. PMID 19682929
    .
  16. .
  17. .
  18. .
  19. .
  20. .
  21. .
  22. .
  23. .
  24. .
  25. .
  26. .
  27. .
  28. .
  29. .
  30. ^ .
  31. ^ "ARCALYSTTM (rilonacept) Product Label" (PDF). Regeneron Pharmaceuticals, Inc. U.S. Food and Drug Administration. Retrieved 5 October 2020.

Further reading

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This page is based on the copyrighted Wikipedia article: IL1B. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy